Concert Pharma (CNCE) Tops Q1 EPS by 2c

Concert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.67), $0.02 better than the analyst estimate of ($0.69).

“We are committed to advancing CTP-543, our breakthrough therapy candidate for moderate to severe alopecia areata. Patients currently lack effective, approved treatment options. We believe we have the potential to provide patients with a new, clinically meaningful and best-in-class treatment option,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We remain on track with our THRIVE-AA Phase 3 clinical program with CTP-543, in support of our New Drug Application that we anticipate filing in early 2023.”

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Sanuwave Q2 2026 revenue tops revised guidance range
• MBX Biosciences names new CEO and CFO amid leadership shift
• Astrana Health names two executives to expand leadership team